# Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers

> **NCT02381470** · PHASE2 · COMPLETED · sponsor: **National University Hospital, Singapore** · enrollment: 58 (actual)

## Conditions studied

- Pulmonary Tuberculosis

## Interventions

- **DRUG:** Faropenem
- **DRUG:** Amoxicillin/clavulanic acid
- **DRUG:** Cefadroxil
- **DRUG:** Rifampicin

## Key facts

- **NCT ID:** NCT02381470
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-11
- **Primary completion:** 2019-09-28
- **Final completion:** 2019-10-02
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2020-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02381470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02381470, "Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02381470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*